Cannabinoids in oral fluid by on-site immunoassay and by GC-MS using two different oral fluid collection devices

Nathalie A. Desrosiers, Garry Milman, Damodara R. Mendu, Dayong Lee, Allan J. Barnes, David A. Gorelick, Marilyn A. Huestis

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Oral fluid (OF) enables non-invasive sample collection for on-site drug testing, but performance of on-site tests with occasional and frequent smokers' OF to identify cannabinoid intake requires further evaluation. Furthermore, as far as we are aware, no studies have evaluated differences between cannabinoid disposition among OF collection devices with authentic OF samples after controlled cannabis administration. Fourteen frequent (≥4 times per week) and 10 occasional (less than twice a week) adult cannabis smokers smoked one 6.8 % Δ9-tetrahydrocannabinol (THC) cigarette ad libitum over 10 min. OF was collected with the StatSure Saliva Sampler, Oral-Eze, and Draeger DrugTest 5000 test cassette before and up to 30 h after cannabis smoking. Test cassettes were analyzed within 15 min and gas chromatography-mass spectrometry cannabinoid results were obtained within 24 h. Cannabinoid concentrations with the StatSure and Oral-Eze devices were compared and times of last cannabinoid detection (t last) and DrugTest 5000 test performance were assessed for different cannabinoid cutoffs. 11-nor-9-Carboxy-THC (THCCOOH) and cannabinol concentrations were significantly higher in Oral-Eze samples than in Stat-Sure samples. DrugTest 5000 t last for a positive cannabinoid test were median (range) 12 h (4-24 h) and 21 h (1-≥30 h) for occasional and frequent smokers, respectively. Detection windows in screening and confirmatory tests were usually shorter for occasional than for frequent smokers, especially when including THCCOOH ≥20 ng L-1 in confirmation criteria. No differences in t last were observed between collection devices, except for THC ≥2 μg L-1. We thus report significantly different THCCOOH and cannabinol, but not THC, concentrations between OF collection devices, which may affect OF data interpretation. The DrugTest 5000 on-site device had high diagnostic sensitivity, specificity, and efficiency for cannabinoids.

Original languageEnglish (US)
Pages (from-to)4117-4128
Number of pages12
JournalAnalytical and Bioanalytical Chemistry
Volume406
Issue number17
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Cannabinoids
Immunoassay
Equipment and Supplies
Dronabinol
Fluids
Cannabis
Cannabinol
Marijuana Smoking
Saliva
Tobacco Products
Gas chromatography
Gas Chromatography-Mass Spectrometry
Mass spectrometry
Screening
Sensitivity and Specificity
Testing
Pharmaceutical Preparations

Keywords

  • Cannabinoid
  • Draeger DrugTest 5000
  • On-site test
  • Oral fluid

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry

Cite this

Desrosiers, N. A., Milman, G., Mendu, D. R., Lee, D., Barnes, A. J., Gorelick, D. A., & Huestis, M. A. (2014). Cannabinoids in oral fluid by on-site immunoassay and by GC-MS using two different oral fluid collection devices. Analytical and Bioanalytical Chemistry, 406(17), 4117-4128. https://doi.org/10.1007/s00216-014-7813-9

Cannabinoids in oral fluid by on-site immunoassay and by GC-MS using two different oral fluid collection devices. / Desrosiers, Nathalie A.; Milman, Garry; Mendu, Damodara R.; Lee, Dayong; Barnes, Allan J.; Gorelick, David A.; Huestis, Marilyn A.

In: Analytical and Bioanalytical Chemistry, Vol. 406, No. 17, 2014, p. 4117-4128.

Research output: Contribution to journalArticle

Desrosiers, NA, Milman, G, Mendu, DR, Lee, D, Barnes, AJ, Gorelick, DA & Huestis, MA 2014, 'Cannabinoids in oral fluid by on-site immunoassay and by GC-MS using two different oral fluid collection devices', Analytical and Bioanalytical Chemistry, vol. 406, no. 17, pp. 4117-4128. https://doi.org/10.1007/s00216-014-7813-9
Desrosiers, Nathalie A. ; Milman, Garry ; Mendu, Damodara R. ; Lee, Dayong ; Barnes, Allan J. ; Gorelick, David A. ; Huestis, Marilyn A. / Cannabinoids in oral fluid by on-site immunoassay and by GC-MS using two different oral fluid collection devices. In: Analytical and Bioanalytical Chemistry. 2014 ; Vol. 406, No. 17. pp. 4117-4128.
@article{a1bb0903c9f74e47b4a3d6151e771bc3,
title = "Cannabinoids in oral fluid by on-site immunoassay and by GC-MS using two different oral fluid collection devices",
abstract = "Oral fluid (OF) enables non-invasive sample collection for on-site drug testing, but performance of on-site tests with occasional and frequent smokers' OF to identify cannabinoid intake requires further evaluation. Furthermore, as far as we are aware, no studies have evaluated differences between cannabinoid disposition among OF collection devices with authentic OF samples after controlled cannabis administration. Fourteen frequent (≥4 times per week) and 10 occasional (less than twice a week) adult cannabis smokers smoked one 6.8 {\%} Δ9-tetrahydrocannabinol (THC) cigarette ad libitum over 10 min. OF was collected with the StatSure Saliva Sampler, Oral-Eze, and Draeger DrugTest 5000 test cassette before and up to 30 h after cannabis smoking. Test cassettes were analyzed within 15 min and gas chromatography-mass spectrometry cannabinoid results were obtained within 24 h. Cannabinoid concentrations with the StatSure and Oral-Eze devices were compared and times of last cannabinoid detection (t last) and DrugTest 5000 test performance were assessed for different cannabinoid cutoffs. 11-nor-9-Carboxy-THC (THCCOOH) and cannabinol concentrations were significantly higher in Oral-Eze samples than in Stat-Sure samples. DrugTest 5000 t last for a positive cannabinoid test were median (range) 12 h (4-24 h) and 21 h (1-≥30 h) for occasional and frequent smokers, respectively. Detection windows in screening and confirmatory tests were usually shorter for occasional than for frequent smokers, especially when including THCCOOH ≥20 ng L-1 in confirmation criteria. No differences in t last were observed between collection devices, except for THC ≥2 μg L-1. We thus report significantly different THCCOOH and cannabinol, but not THC, concentrations between OF collection devices, which may affect OF data interpretation. The DrugTest 5000 on-site device had high diagnostic sensitivity, specificity, and efficiency for cannabinoids.",
keywords = "Cannabinoid, Draeger DrugTest 5000, On-site test, Oral fluid",
author = "Desrosiers, {Nathalie A.} and Garry Milman and Mendu, {Damodara R.} and Dayong Lee and Barnes, {Allan J.} and Gorelick, {David A.} and Huestis, {Marilyn A.}",
year = "2014",
doi = "10.1007/s00216-014-7813-9",
language = "English (US)",
volume = "406",
pages = "4117--4128",
journal = "Fresenius Zeitschrift fur Analytische Chemie",
issn = "0016-1152",
publisher = "Springer Verlag",
number = "17",

}

TY - JOUR

T1 - Cannabinoids in oral fluid by on-site immunoassay and by GC-MS using two different oral fluid collection devices

AU - Desrosiers, Nathalie A.

AU - Milman, Garry

AU - Mendu, Damodara R.

AU - Lee, Dayong

AU - Barnes, Allan J.

AU - Gorelick, David A.

AU - Huestis, Marilyn A.

PY - 2014

Y1 - 2014

N2 - Oral fluid (OF) enables non-invasive sample collection for on-site drug testing, but performance of on-site tests with occasional and frequent smokers' OF to identify cannabinoid intake requires further evaluation. Furthermore, as far as we are aware, no studies have evaluated differences between cannabinoid disposition among OF collection devices with authentic OF samples after controlled cannabis administration. Fourteen frequent (≥4 times per week) and 10 occasional (less than twice a week) adult cannabis smokers smoked one 6.8 % Δ9-tetrahydrocannabinol (THC) cigarette ad libitum over 10 min. OF was collected with the StatSure Saliva Sampler, Oral-Eze, and Draeger DrugTest 5000 test cassette before and up to 30 h after cannabis smoking. Test cassettes were analyzed within 15 min and gas chromatography-mass spectrometry cannabinoid results were obtained within 24 h. Cannabinoid concentrations with the StatSure and Oral-Eze devices were compared and times of last cannabinoid detection (t last) and DrugTest 5000 test performance were assessed for different cannabinoid cutoffs. 11-nor-9-Carboxy-THC (THCCOOH) and cannabinol concentrations were significantly higher in Oral-Eze samples than in Stat-Sure samples. DrugTest 5000 t last for a positive cannabinoid test were median (range) 12 h (4-24 h) and 21 h (1-≥30 h) for occasional and frequent smokers, respectively. Detection windows in screening and confirmatory tests were usually shorter for occasional than for frequent smokers, especially when including THCCOOH ≥20 ng L-1 in confirmation criteria. No differences in t last were observed between collection devices, except for THC ≥2 μg L-1. We thus report significantly different THCCOOH and cannabinol, but not THC, concentrations between OF collection devices, which may affect OF data interpretation. The DrugTest 5000 on-site device had high diagnostic sensitivity, specificity, and efficiency for cannabinoids.

AB - Oral fluid (OF) enables non-invasive sample collection for on-site drug testing, but performance of on-site tests with occasional and frequent smokers' OF to identify cannabinoid intake requires further evaluation. Furthermore, as far as we are aware, no studies have evaluated differences between cannabinoid disposition among OF collection devices with authentic OF samples after controlled cannabis administration. Fourteen frequent (≥4 times per week) and 10 occasional (less than twice a week) adult cannabis smokers smoked one 6.8 % Δ9-tetrahydrocannabinol (THC) cigarette ad libitum over 10 min. OF was collected with the StatSure Saliva Sampler, Oral-Eze, and Draeger DrugTest 5000 test cassette before and up to 30 h after cannabis smoking. Test cassettes were analyzed within 15 min and gas chromatography-mass spectrometry cannabinoid results were obtained within 24 h. Cannabinoid concentrations with the StatSure and Oral-Eze devices were compared and times of last cannabinoid detection (t last) and DrugTest 5000 test performance were assessed for different cannabinoid cutoffs. 11-nor-9-Carboxy-THC (THCCOOH) and cannabinol concentrations were significantly higher in Oral-Eze samples than in Stat-Sure samples. DrugTest 5000 t last for a positive cannabinoid test were median (range) 12 h (4-24 h) and 21 h (1-≥30 h) for occasional and frequent smokers, respectively. Detection windows in screening and confirmatory tests were usually shorter for occasional than for frequent smokers, especially when including THCCOOH ≥20 ng L-1 in confirmation criteria. No differences in t last were observed between collection devices, except for THC ≥2 μg L-1. We thus report significantly different THCCOOH and cannabinol, but not THC, concentrations between OF collection devices, which may affect OF data interpretation. The DrugTest 5000 on-site device had high diagnostic sensitivity, specificity, and efficiency for cannabinoids.

KW - Cannabinoid

KW - Draeger DrugTest 5000

KW - On-site test

KW - Oral fluid

UR - http://www.scopus.com/inward/record.url?scp=84903786712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903786712&partnerID=8YFLogxK

U2 - 10.1007/s00216-014-7813-9

DO - 10.1007/s00216-014-7813-9

M3 - Article

VL - 406

SP - 4117

EP - 4128

JO - Fresenius Zeitschrift fur Analytische Chemie

JF - Fresenius Zeitschrift fur Analytische Chemie

SN - 0016-1152

IS - 17

ER -